Targeting the chemokine receptor CCR5: good for HIV, what about other viruses?

J Infect Dis. 2011 Jan 15;203(2):292; author reply 293. doi: 10.1093/infdis/jiq032.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • CCR5 Receptor Antagonists*
  • Clinical Trials, Phase II as Topic
  • HIV Infections / drug therapy*
  • Humans
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Receptors, CCR5 / immunology
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • CCR5 Receptor Antagonists
  • Piperazines
  • Pyrimidines
  • Receptors, CCR5
  • vicriviroc